Preparation and evaluation of nanoparticles loaded ophthalmic <i>in situ</i> gel

Kesarla, Rajesh; Tank, Tanvi; Vora, Pratik Ashwinbhai; Shah, Tanvi; Parmar, Sagar; Omri, Abdelwahab

doi:10.3109/10717544.2014.987333

Cited by 73 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparative in vitro drug release study between surface modified PLGA 75:25 and PLGA 50:50 nanoparticles was carried out for 10 h as per the procedure R. Kesarrla et al 2016 [ 19 ]. Surface modified PLGA 75:25 nanoparticles showed 58.481 ± 1.383% drug release at the end of 10 h. On the other hand surface modified PLGA 50:50 polymer showed 74.178 ± 1.384% drug release at the end of 10 h. In both case drug release pattern was found to be biphasic which might be due to initial burst release [ 26 , 27 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences

Laddha

Kshirsagar

2020

Heliyon

View full text Add to dashboard Cite

Diabetic retinopathy is one of the worst complications of diabetes and it is treated by invasive method. We prepared a surface modified poly (D, L-lactide-co-glycolide) i.e. PLGA nanoparticles for delivery of pioglitazone-a peroxisome proliferator-activated receptor-gamma agonist to posterior segment of the eye by topical administration. The present study investigated two grades of PLGA viz. 75:25 and 50:50. Surface modification was performed using polysorbate 80. Nanoparticles were prepared by single emulsion solvent evaporation method and optimized by using 3-factor 3-level Box-Behnken statistical design. Mean particle size, PDI and entrapment efficiency for optimized batch of PLGA 75:25 was found to be 163.23 nm, 0.286 and 91%, whereas; for PLGA 50:50 it was 171.7 nm, 0.280 and 93% respectively. DSC confirms the molecular dispersion of drug in polymer. In vitro release study showed biphasic drug release pattern with 58.48 ± 1.38% and 74.17 ± 1.38% cumulative drug release by PLGA 75:25 and 50:50 nanoparticles at the end of 10h. The release profile of pioglitazone from nanoparticles appeared to fit best with Higuchi model. In vivo study on rat showed dose dependent reduction in vascular endothelial growth factor concentration in vitreous fluid. The study reveals significance of peroxisome proliferator-activated receptor-gamma in management of diabetic retinopathy.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The in vitro release study of surface modified PLGA nanoparticles of pioglitazone (PLGA 75:25 and 50:50) was performed in triplicate as per procedure given by R. Kesarla et al (2016) and Salama, Mahmoud and Kamel (2016) [18,19]. Phosphate buffer pH 7.4 was used as dissolution medium.…”

Section: In-vitro Drug Releasementioning

confidence: 99%

Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences

Laddha

Kshirsagar

2020

Heliyon

View full text Add to dashboard Cite

show abstract

“…21,[45][46][47][48][49][50][51][52][53][54][55][56][57][58][59] Some examples of recent ndings with the above-mentioned nanocarriers for the treatment of ophthalmic diseases are compiled in Table 3. [60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79]…”

Section: Importance Of Nanomedicine In Ocular Drug Delivery Systemsmentioning

confidence: 99%

Nanocarriers for ocular drug delivery: current status and translational opportunity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…All the formulations showed 80-99% drug release between 660-720 min. Kesaarlaet al also observed that nanoparticles with in situ gel formulation provide sustained drug release for 12 h [17].…”

Section: Characterization Of In-situ Gel Containing Nanoparticles Phmentioning

confidence: 94%

Evaluation of in situ gel forming system loaded with etoricoxib and herbal adjuvant nanoparticles against human colon cancer cell lines (HT-29)

2020

Lett Appl NanoBioSci

View full text Add to dashboard Cite

The aim of the research work was to fabricate the nanosuspension of etoricoxib with polyherbal components (extract of ginger root and basil leaf) to enhance the solubility of API; furthermorein situ gel forming system for stomach specific drug delivery was prepared utilizing formulated nanosuspension as base. The objective of the present research is to enhance the solubility of poorly aqueous soluble drug by fabricating nanoparticles and improve their residence time within stomach by formulating in situ gel forming system. Tamarind seed polysaccharide as polymer, etoricoxib as drug, ethanolic extract of ginger (GE) and basil (BE), was used for preparation of nanoparticles.Solvent antisolvent precipitation method was used to prepare nanoparticles. The fabricated nanoparticles were evaluated for various parameters such as physical appearance, Scanning electron microscope, drug content, in-vitro drug release. For preparation of in-situ gel containing nanoparticles, tamarind seed polysaccharides, calcium carbonate and sodium alginate were used. The prepared formulations were evaluated for different characterization parameters such as,- pH, viscosity, floating behaviour, drug content, in-vitro drug release and in-vitro cytotoxic study. The in-situ gel containing nanoparticles were successfully prepared and evaluated. Firstly, the nanoparticles were evaluated for physical appearance, Scanning electron microscope, drug content, in-vitro drug release and found that the formulations were clear as well as homogenous, size of nanoparticles was evaluated in the range of 498nm to 587nm, the drug content of etoricoxib was found in the range of 71.38±0.01 (F5) to 79.45±0.01 (F6), the drug content of GE was found in the range of 69.25±0.05 (F4) to 74.25±0.02 (F1) and the drug content of BE was 69.48±0.09 (F1) to 75.59±0.08 (F6). The drug release was taken up to 12 h and found to be 99%. In-situ gel containing nanoparticles were also evaluated for different parameters such as pH, viscosity, floating behaviour, drug content, and in-vitro drug release. The pH of the prepared formulation was found to be in the range of 7.1±0.04 to 7.5±0.02. The viscosity of the prepared formulation was found in the range of 11.25±0.023 to 12.78 ±0.025. The lag time was found in the range of 11 to 20 sec and floating time was upto 24 h. The drug release was taken up to 8 h and found to be 99±0.2%. It can be concluded that etoricoxib with phytoconstituents (GE and BE) improved its potential to control the growth of human colon cancer cell line (HT-29) in in-vitro conditions. It was concluded from the findings that the in-situ gel containing nanoparticles of etoricoxib from solvent antisolvent method was successfully prepared and found that it has improved the solubility of the poorly soluble drug etoricoxib and dissolution rates.

show abstract

Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel

Cited by 73 publications

References 24 publications

Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences

Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences

Nanocarriers for ocular drug delivery: current status and translational opportunity

Evaluation of in situ gel forming system loaded with etoricoxib and herbal adjuvant nanoparticles against human colon cancer cell lines (HT-29)

Contact Info

Product

Resources

About